Get the Stockscreener App
7.91
2.83%
-0.23
Aurinia Pharmaceuticals Inc stock is traded at $7.91, with a volume of 935.07K.
It is down -2.83% in the last 24 hours and down -3.42% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$8.14
Open:
$8.09
24h Volume:
935.07K
Relative Volume:
0.78
Market Cap:
$1.10B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-14.92
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-2.94%
1M Performance:
-3.42%
6M Performance:
-17.17%
1Y Performance:
+42.78%
1-Day Range:
$7.91
$8.13
1-Week Range:
$7.91
$8.315
52-Week Range:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
7.91 | 1.10B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™ - News Channel Nebraska
California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
As Edmonton biotech industry booms, Launa Aspeslet steps up to guide further success - Taproot Edmonton
Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - mx.advfn.com
Millennium Management LLC Increases Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SDIG, AUPH and LICY - ACCESS Newswire
(AUPH) Trading Signals - news.stocktradersdaily.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.27 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - InsuranceNewsNet
Ameriprise Financial Inc. Acquires 26,981 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AUPH, IRNT and RSKD - ACCESS Newswire
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
BNP Paribas Financial Markets Sells 14,003 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Nuveen Asset Management LLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Cetera Investment Advisers Purchases 2,000 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
(AUPH) Technical Data - news.stocktradersdaily.com
Deutsche Bank AG Purchases 50,575 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert - Benzinga
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial R - GuruFocus
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus
Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Leerink Partnrs Has Positive Outlook of AUPH Q2 Earnings - Defense World
Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN
Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa
Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus
Price T Rowe Associates Inc. MD Has $468,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Company News for May 13, 2025 - Yahoo Finance
Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Document - SEC.gov
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Aurinia: Q1 Earnings Snapshot - MySA
Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
Leerink maintains Aurinia stock Outperform with $10 target - Investing.com
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India
AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):